Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7244
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Detroit, Michigan. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 397–408 of 7,244 matching trials in Detroit, MI.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Phase 3 Interventional

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164
View directory record Official record
Conditions
Von Hippel-Lindau Disease, Malignant Neoplasms
Interventions
Belzutifan, Nivolumab, Lenvatinib, Cabozantinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
8
States / cities
Boston, Massachusetts • Detroit, Michigan • Philadelphia, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Active, not recruiting Phase 3 Interventional Results available

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Drug · Other
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

NCT02112916
View directory record Official record
Conditions
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Radiation Therapy, Thioguanine, Vincristine, Vincristine Sulfate
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
188
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01386385
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
232
States / cities
Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Everolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Completed Phase 3 Interventional

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

NCT03989206
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
136
States / cities
Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Cabozantinib, Placebo
Drug
Lead sponsor
Exelixis
Industry
Eligibility
16 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
31
States / cities
Newport Beach, California • Sacramento, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Not yet recruiting Not applicable Interventional

The PIONEER Comparative Effectiveness Study - Project 2

NCT07829107
View directory record Official record
Conditions
Head Injury Trauma, Traumatic Brain Injury, Mild
Interventions
Clinical pathway 1: Guidelines plus biomarkers, Clinical guidelines only
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Sylmar, California • Torrance, California • Clinton Township, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976
View directory record Official record
Conditions
Autoimmune Haemolytic Anaemia
Interventions
rilzabrutinib, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Recruiting Not applicable Interventional

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

NCT07214376
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Interventions
Pulmonary Artery Denervation (PADN), Sham procedure control
Device
Lead sponsor
Pulnovo Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
14
States / cities
Tucson, Arizona • New Haven, Connecticut • Weston, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Recruiting Phase 3 Interventional

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196
View directory record Official record
Conditions
Immunoglobulin G4 Related Disease
Interventions
Rilzabrutinib, Placebo, Glucocorticoid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
21
States / cities
Fontana, California • Sacramento, California • San Jose, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST
Recruiting Phase 1Phase 2 Interventional

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497
View directory record Official record
Conditions
Locally Advanced / Metastatic Solid Tumors
Interventions
CR-001, Paclitaxel, trifluridine and tipiracil, Pemetrexed, Carboplatin, Oxaliplatin, Gemcitabin, Cisplatin, Capecitabine, FOLFOX
Drug
Lead sponsor
Crescent Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 8:21 PM EST